Literature DB >> 2876492

The influence of a long-acting somatostatin analogue on splanchnic haemodynamics and metabolism in healthy subjects and patients with liver cirrhosis.

J Wahren, L S Eriksson.   

Abstract

The influence of a long-acting somatostatin octapeptide analogue (SMS 201-995) on splanchnic circulation and metabolism has been studied in healthy subjects and in patients with liver cirrhosis. In healthy subjects doses of 5, 10, 50, or 100 micrograms SMS and in the cirrhotic patients 25 micrograms SMS were infused intravenously during 1 h. Measurements were obtained before, during, and for 1 h after SMS infusion. SMS infusion in healthy subjects resulted in a 25-35% reduction in hepatic blood flow. This effect was largely independent of the dose used. Splanchnic oxygen uptake was unchanged before and during SMS infusion. Insulin and glucagon levels fell markedly in response to SMS administration, and the blood concentration and splanchnic output of glucose decreased transiently. Patients with liver cirrhosis responded to SMS infusion similarly to the healthy subjects. Hepatic blood flow decreased by 25-35% and remained suppressed for at least 1 h after infusion. Wedge hepatic venous pressure was 18 +/- 2 mm Hg in the basal state and decreased progressively during and after SMS infusion (60 min after infusion, 15 +/- 2 mm Hg; P less than 0.01). The marked hyperinsulinaemia and hyperglucagonaemia seen in the basal state decreased significantly during SMS administration. As in the case of the controls, blood concentration and splanchnic output of glucose fell transiently during and after SMS infusion. It is concluded that SMS exerts a marked and prolonged suppressive effect on hepatic blood flow in both healthy subjects and patients with liver cirrhosis.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 2876492     DOI: 10.3109/00365528609087437

Source DB:  PubMed          Journal:  Scand J Gastroenterol Suppl        ISSN: 0085-5928


  9 in total

Review 1.  Somatostatin in portal hypertension.

Authors:  J S Morgan; R J Groszmann
Journal:  Dig Dis Sci       Date:  1989-03       Impact factor: 3.199

2.  Treatment of the dumping syndrome with the somatostatin analogue SMS 201-995.

Authors:  W P Hopman; R G Wolberink; C B Lamers; J H Van Tongeren
Journal:  Ann Surg       Date:  1988-02       Impact factor: 12.969

3.  Effect of a somatostatin analogue (SMS 201-995) on hemodynamics and glucagon secretion in cirrhotic rats.

Authors:  N Hori; T Okanoue; Y Sawa; T Mori; K Kashima
Journal:  Gastroenterol Jpn       Date:  1993-04

4.  Improvement in the intestinal processes of hydroelectrolytic absorption and secretion in abdominal pathologies of surgical interest treated with SMS 201-995: experimental protocol.

Authors:  F F Guiró; G Bertolini; J V Salas
Journal:  Surg Today       Date:  1999       Impact factor: 2.549

5.  Long-term octreotide treatment reduced hyperinsulinemia, excess body weight and skin lesions in severe obesity with acanthosis nigricans.

Authors:  M Lunetta; M Di Mauro; R Le Moli; S Burrafato
Journal:  J Endocrinol Invest       Date:  1996-11       Impact factor: 4.256

6.  Somatostatin analog sandostatin and inhibition of tumor growth in patients with metastatic endocrine gastroenteropancreatic tumors.

Authors:  R Arnold; C Neuhaus; R Benning; W B Schwerk; M E Trautmann; K Joseph; C Bruns
Journal:  World J Surg       Date:  1993 Jul-Aug       Impact factor: 3.352

7.  Assessment of hepatic blood flow using continuous infusion of high clearance drugs.

Authors:  R C Schoemaker; J Burggraaf; A F Cohen
Journal:  Br J Clin Pharmacol       Date:  1998-05       Impact factor: 4.335

8.  Somatostatin prevents the postoperative increases in plasma amino acid clearance and urea synthesis after elective cholecystectomy.

Authors:  H Heindorff; P Billesbølle; S L Pedersen; R Hansen; H Vilstrup
Journal:  Gut       Date:  1995-05       Impact factor: 23.059

9.  Hemodynamic effects of combined treatment with somatostatin analogue (SMS 201-995) and low-dose isosorbide dinitrate on portal hypertension in conscious cirrhotic rats.

Authors:  N Hori; T Okanoue; Y Sawa; Y Itoh; T Mori; S Takami; K Kashima
Journal:  J Gastroenterol       Date:  1994-08       Impact factor: 7.527

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.